Cureus
Does Combination Therapy With a Glucagon-Like Peptide-1 Receptor Agonist and a Sodium-Glucose Cotransporter 2 Inhibitor Enhance Cardiovascular and Renal Protection in People With Type 2 Diabetes Mellitus?
Cohort study of 238 peopleInterventions
- GLP-1 receptor agonists + SGLT2 inhibitors
- GLP-1 and incretin signalling
- Type 2 diabetes
- Chronic kidney disease
- Heart failure
- Humans
